Abstracts tagged "Epidemiologic methods"

Abstract Number: 1382 • 2014 ACR/ARHP Annual Meeting
The Longitudinal Course of Fatigue in Rheumatoid Arthritis – Results from the Norfolk Arthritis Register
Katie L Druce¹, Gareth T Jones², Gary J. Macfarlane¹, Suzanne M. Verstappen³ and Neil Basu¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Musculoskeletal Research Collaboration (Epidemiology Group),, University of Aberdeen, Aberdeen, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Fatigue is common and burdensome in Rheumatoid Arthritis (RA). Though RA fatigue progression varies significantly between individuals, to date, published analyses have only considered…
Abstract Number: 2887 • 2014 ACR/ARHP Annual Meeting
Post-Menopausal Factors and the Risk of Seropositive and Seronegative Rheumatoid Arthritis Phenotypes: Results from the Nurses’ Health Study
Camilla Bengtsson¹, Susan Malspeis², Jeffrey A. Sparks³, Karen H. Costenbader³ and Elizabeth W. Karlson³, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Among women, the peak incidence of rheumatoid arthritis (RA) is reported to be 45-74 years of age. In addition, it has been suggested that…
Abstract Number: 1226 • 2014 ACR/ARHP Annual Meeting
Studying Patients with Autoinflammatory Diseases: The Past, Present, and a Perspective for the Future
Jonathan S. Hausmann^1,2, Catherine Biggs³, Donald P. Goldsmith⁴ and Fatma Dedeoglu^1,5, ¹Rheumatology, Boston Children's Hospital, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ³Program in Rheumatology, Divison of Immunoloty, Boston Children's Hospital, Boston, MA, ⁴Pediatric Rheumaology, St Christopher's Hospital for Children/ Drexel College of Medicine, Philadelphia, PA, ⁵on behalf of CARRAnet Investigators, Palo Alto, CA
Background/Purpose: Autoinflammatory diseases (AIDs) are uncommon disorders characterized by recurrent episodes of systemic and organ-specific inflammation. Because of their rarity, finding large numbers of patients…
Abstract Number: 2888 • 2014 ACR/ARHP Annual Meeting
Amount of Smoking, Duration of Smoking Cessation, and Their Interaction with Silica Exposure in the Risk of Rheumatoid Arthritis: Results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study
Xia Jiang¹, Camilla Bengtsson², Henrik Källberg³, Lars Klareskog⁴ and Lars Alfredsson², ¹Nobels vag13, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Exposure to silica is a well-defined inhalation exposure, and is known to be associated with moderately increased rheumatoid arthritis (RA) risk, with the effect…
Abstract Number: 1076 • 2014 ACR/ARHP Annual Meeting
U.S. Geographic Trends in the Distribution and Treatment Practices of Juvenile Systemic Lupus Erythematosus: An Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Jennifer M.P. Woo^1,2, Ornella J. Rullo¹, Deborah K. McCurdy³ and The CARRA Registry Investigators⁴, ¹Pediatric Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose: The treatment of juvenile systemic lupus erythematosus (jSLE) often requires complex medication regimens in order to address the different disease manifestations. Despite the limited…
Abstract Number: 2892 • 2014 ACR/ARHP Annual Meeting
The Relative Risk of Incident NON-Ischemic Heart Failure in Prevalent Rheumatoid Arthritis
Ängla Mantel¹, Marie Holmqvist², Johan Askling³, Lars Lund⁴ and Daniel Andersson⁵, ¹Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, ²Karolinska Institutet, Unit of Clinical Epidemiology, Department of medicine, Stockholm, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Unit of Cardiology section for Heart Failure. Department of Medicine, Stockholm, Sweden, ⁵Karolinska Institutet, Unit of Cardiology section for heart failure. Department of Medicine, Stockholm, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) may be at increased risk of developing heart failure (HF). Inflammatory activity has been linked to the pathogenesis of…
Abstract Number: 928 • 2014 ACR/ARHP Annual Meeting
A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Alessandro Consolaro¹, Amita Aggarwal², Troels Herlin³, Olga Vougiouka⁴, Rubén Burgos-Vargas⁵, Ilonka Orban⁶, Nahid Shafaie⁷, Maria Trachana⁸, Lidia Rutkowska-Sak⁹, Ingrida Rumba-Rozenfelde¹⁰, Dimitrina Mihaylova¹¹, Alberto Martini^12,13 and Angelo Ravelli^1,14, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, ⁵Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁷Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran, ⁸Aristotle University, Thessaloniki, Greece, ⁹Institute of Rheumatology, Warsaw, Poland, ¹⁰University of Latvia, Riga, Latvia, ¹¹University Children Hospital, Sofia, Bulgaria, ¹²Istituto Giannina Gaslini, Genova, Italy, ¹³University of Genova, Genova, Italy, ¹⁴Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose The epidemiology of juvenile idiopathic arthritis (JIA) is known to be variable worldwide and the therapeutic approach to JIA is not standardized. Moreover, the…
Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Nigil Haroon¹, Nisha Nigil Haroon², Ping Li³, Michael Paterson³ and Robert D. Inman⁴, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…
Abstract Number: 896 • 2014 ACR/ARHP Annual Meeting
Development of Fibromyalgia and Polysymptomatic Distress Definitions in the National Health Interview Survey
Brian Walitt¹, Richard Nahin², Robert S. Katz³, Martin J. Bergman⁴ and Frederick Wolfe⁵, ¹MedStar Health, Washington, DC, ²National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethedsa, MD, ³Rush Medical College, Chicago, IL, ⁴Taylor Hospital, Ridley Park, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: A detailed understanding of fibromyalgia and its symptoms in the US population would be valuable. The National Health Interview Survey (NHIS) is the principal…
Abstract Number: 2466 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Rheumatoid Arthritis (RA) Among Shared Epitope-Negative (SE-) Mothers with Shared Epitope-Positive (SE+) Children
Giovanna Cruz¹, Lindsey A. Criswell², Xiaorong Shao³, Hong L. Quach¹, Janelle Noble⁴, Nikolaos Patsopoulos⁵, Michael Busch⁶ and Lisa F. Barcellos¹, ¹Epidemiology, University of California, Berkeley, Berkeley, CA, ²Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Genetic Epidemiology and Genomics Lab, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ⁴Children's Hospital Oakland Research Institute (CHORI), Oakland, CA, ⁵Division of Genetics, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁶Blood Systems Research Institute, San Francisco, CA
Background/Purpose RA (RA [MIM 180300]) disproportionately affects women of reproductive age, implicating pregnancy-related factors. Fetal microchimerism (FMC), or the persistence of a small population of…
Abstract Number: 822 • 2014 ACR/ARHP Annual Meeting
Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study
Deepan Dalal¹, Maureen Dubreuil^2,3, Yuqing Zhang⁴, Christine Peloquin⁵, Tuhina Neogi⁴, Hyon K. Choi² and David T. Felson⁶, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology, VA Boston Healthcare System, Jamaica Plain, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Certain non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with an increased risk of myocardial infarction (MI). MI risk for different NSAIDs varies largely because…
Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Naonobu Sugiyama M.D., Ph.D¹, Tatsunori Murata, M.S.², Yosuke Morishima³, Yuri Fukuma⁴, Yoshiyuki Shibasaki⁴ and Lisa Marshall⁵, ¹Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ²Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, ³RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁴Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁵Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…
Abstract Number: 791 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Francesco Muratore¹, Alberto Cavazza², Giovanna Restuccia³, Pierluigi Macchioni¹, Giuseppe Germanò¹, Nicolò Pipitone¹, Gianluigi Bajocchi⁴ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Japan
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). In some cases of…
Abstract Number: 2071 • 2014 ACR/ARHP Annual Meeting
Chronic Widespread Pain Versus Multi-Site Pain: Does the Distribution Matter?
Marcus Beasley and Gary J. Macfarlane, Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: The ACR 1990 diagnostic criteria for fibromyalgia includes a definition for chronic widespread pain (CWP) that depends on a particular distribution of pain sites.…
Abstract Number: 786 • 2014 ACR/ARHP Annual Meeting
The Incidence and Mortality Rates of Giant Cell Arteritis in Southern Norway Are Lower Than Previous Reported
Andreas P. Diamantopoulos¹, Glenn Haugeberg¹, Lisa Amundsen², Elisabeth Wigaard¹, Dag Magnar Soldal¹ and Geirmund Myklebust¹, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Hospital of Southern Norway Trust, Kristiansand, Norway
The Incidence and Mortality rates of Giant Cell Arteritis in Southern Norway are lower than Previous ReportedBackground/Purpose Giant cell arteritis (GCA) is the most common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.